Project Grant R01AG089467
Award Date
5/15/25
Completion Date
2/28/30
Dollars Obligated
$815K
Federal Agency
National Institute on Aging
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
The National Institutes of Health National Institute on Aging awarded $3,024,000 under the Aging Research federal grant program (CFDA 93.866) to the Massachusetts General Hospital on September 30, 2022 for a project concluding on August 31, 2025. The award will support research into discovering sex-linked genes on the inactive X chromosome that may influence female vulnerability to Alzheimer's disease pathology. The awardee will employ genomic, transcriptomic, and epigenetic analysis to...
This federal Project Grant award, provided by the National Institute on Aging (CFDA 93.866 Aging Research), aims to investigate the mechanisms by which sex differences and angiotensin II signaling influence the development and progression of Alzheimer's disease (AD). The $2,114,698 grant, awarded to the University of North Texas Health Science Center at Fort Worth, will fund research over a 5-year period from Aug 2024 to Apr 2029. The key products and services to be delivered under this grant...
This Project Grant award from the National Institute on Aging (NIA) under CFDA 93.866 - Aging Research aims to investigate the mechanisms by which the Alzheimer's disease risk factor APOE4 interacts with sex and aging to drive neuronal dysfunction and cognitive decline. The $804,450 award to the J. David Gladstone Institutes will fund a multi-level research effort leveraging advanced techniques like single-nucleus RNA sequencing and in vivo brain activity monitoring. The key objectives are to:...
The National Institutes of Health's National Institute on Aging (CFDA 93.866 - Aging Research) awarded a $851,002 Project Grant to Arizona State University to conduct a systematic investigation of the genetic contributions of sex chromosomes to Alzheimer's disease (AD). The 2-year project, running from December 2024 to November 2026, will apply a sex-chromosome-aware alignment approach to reanalyze Next-Generation Sequencing data from large AD clinical cohorts. The goal is to identify variants...
This federal Project Grant award of $2,309,934 from the National Institute on Aging (NIA) Aging Research program (CFDA 93.866) supports research into the role of brain aromatase and its impact on Alzheimer's disease (AD) development and progression. The key objectives are to: Examine whether downregulation or inhibition of aromatase is associated with worsened cognitive decline in AD rodent models, and if photobiomodulation (PBM) or estradiol (E2) treatment can prevent aromatase decline and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $431,750 to Arizona State University (ASU) to investigate the interaction between biological sex and the APOE genotype in modulating the risk of Alzheimer's disease onset and progression. The research will utilize human induced pluripotent stem cell lines with different APOE genotypes and sex chromosome complements to study how APOE and sex influence amyloid-beta processing, tau...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $461,146 to Yale University to investigate the dysregulation of cortical astrocytes, a key cell type involved in inflammatory responses and synaptic function, in Alzheimer's disease (AD) models. The research aims to longitudinally track changes in astrocytic and neuromodulatory signaling across the cortex in awake, behaving animals using novel imaging approaches. The goal is to elucidate the...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $3,281,385 to the University of California, San Diego (UCSD) to examine the role of specific phenotypes, such as sex/gender, APOE4 status, and polygenic hazard scores, on response to drug or lifestyle interventions in existing Alzheimer's disease clinical trial datasets. The project aims to leverage 30 years of harmonized data from 14,602 participants across multiple clinical trials to...
This $459,076 federal Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) will support research into the early transcriptional and pathological changes in vulnerable brain regions during the prodromal stage of Alzheimer's disease (AD). The project will leverage single-nucleus RNA sequencing and targeted mass spectrometry analysis of postmortem brain samples from individuals with early-stage AD pathology to profile gene expression changes and identify...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $372,690 to the University of California, Berkeley to conduct research aimed at understanding the heterogeneous causal pathophysiology of Alzheimer's disease (AD). The key objectives are to: 1) Develop new statistical methods for uncovering heterogeneous causal relationships among amyloid-beta, tau accumulation, and cognition across diverse AD datasets; 2) Apply these methods to reveal optimal...